How a gym supplement ended up in my ALS research notes
A Curalysis blog proposes testing β-hydroxy-β-methylbutyrate (HMB), a supplement, to see whether it lowers IGFBP7 levels in people with amyotrophic lateral sclerosis (ALS). The idea is based on reported links between IGFBP7, insulin-like growth factor 1 signaling and ALS reversal cases. The blog says the pilot is planned and that HMB is not an established treatment.
Why this matters
This may interest people with ALS and researchers looking for ways to test the IGFBP7 pathway. However, the proposal does not yet show that HMB changes disease progression, improves symptoms or protects motor neurons, and it does not change treatment recommendations.
Limitations and context
The source is a first-party Curalysis blog, not a reported clinical trial or an independent peer-reviewed assessment of HMB in ALS. The proposed pilot has not yet provided results. The blog itself says the biological links are early, that blood IGFBP7 may not reflect levels in the brain or spinal cord, and that correlation does not prove cause. Its account of related studies and collaborations is not independently documented in the supplied source.